药物性肝损伤病理学的特征及鉴别诊断

杨永峰

doi:10.3969/j.issn.1001-5256.2021.11.005

药物性肝损伤病理学的特征及鉴别诊断

DOI: 10.3969/j.issn.1001-5256.2021.11.005

杨永峰^,

南京中医药大学附属南京医院(南京市第二医院)，南京大学教学医院肝病科，南京 210003

基金项目:

国家自然科学基金面上项目 (81970454)

详细信息

通信作者:
杨永峰，yangyongfeng@njucm.edu.cn

中图分类号: R575
计量
- 文章访问数: 759
- HTML全文浏览量: 230
- PDF下载量: 205
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-15
- 录用日期: 2021-09-15
- 出版日期: 2021-11-20

Pathological features and pathological diagnosis of drug-induced liver injury

Yongfeng YANG^,

Department of Hepatology, Nanjing Hospital Affiliated to Nanjing University of Chinese Medicine & Nanjing Second Hospital, Teaching Hospital of Nanjing University, Nanjing 210003, China

Research funding:

General Project of National Natural Science Foundation of China (81970454)

摘要

摘要: 药物性肝损伤(DILI)肝组织学表现分为炎症坏死型、胆汁淤积型、脂肪变性和脂肪肝炎型、血管损伤型、轻微病变型等多种病理类型。对于疑诊为DILI但又不肯定、不能用DILI一元论解释的肝损伤、多药物接触史而不能确定具体致损药物的DILI、治疗效果不符合预期DILI、慢性DILI等，需要组织病理学进一步鉴别诊断；组织病理学还可用于评估DILI病情轻重和预后。因DILI肝组织病变分布不均一，要有充足的组织样本量才能减少取样误差。由于肝损伤性疾病组织病理学表现“一因多果、多因一果”，病理密切结合临床才能最大可能得出最终诊断，在DILI的组织学诊断过程中临床病理讨论尤为重要。
- 化学性与药物性肝损伤 /
- 病理状态, 体征和症状 /
- 诊断
Abstract: Based on liver histology, drug-induced liver injury (DILI) is classified as various pathological types of inflammatory necrosis, cholestasis, fatty degeneration and fatty liver disease, vascular injury, and minimal lesion. Histopathological examination is required for further differential diagnosis in suspected cases of DILI, liver injury that cannot be explained by DILI monogenesis, DILI cases with a history of exposure to various drugs in which the specific drug causing liver injury cannot be determined, DILI cases with unsatisfactory treatment outcome, and chronic DILI, and histopathological examination can also be used to evaluate the severity and prognosis of DILI. Since liver lesions are unevenly distributed in DILI, adequate tissue samples are needed to reduce sampling error. The histopathological manifestation of liver injury diseases has the features of "one cause with multiple results and one result with multiple causes", and a combination of pathological examination and clinical symptoms can help to make a confirmed diagnosis, suggesting that clinicopathological discussion is of great importance in the histological diagnosis of DILI.
- Chemical and Drug-Induced Liver Injury /
- Pathological Conditions, Signs and Symptoms /
- Diagnosis

HTML全文

图 1 疑诊DILI时的组织病理学鉴别路径^[20]

下载: 全尺寸图片幻灯片

参考文献(21)

[1]	GASMI B, KLEINER DE. Liver histology: Diagnostic and prognostic features[J]. Clin Liver Dis, 2020, 24(1): 61-74. DOI: 10.1016/j.cld.2019.09.004.
[2]	KLEINER DE, CHALASANI NP, LEE WM, et al. Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations[J]. Hepatology, 2014, 59(2): 661-670. DOI: 10.1002/hep.26709.
[3]	TSUTSUI A, HARADA K, TSUNEYAMA K, et al. Histopathological analysis of autoimmune hepatitis with "acute" presentation: Differentiation from drug-induced liver injury[J]. Hepatol Res, 2020, 50(9): 1047-1061. DOI: 10.1111/hepr.13532.
[4]	COHEN JV, DOUGAN M, ZUBIRI L, et al. Liver biopsy findings in patients on immune checkpoint inhibitors[J]. Mod Pathol, 2021, 34(2): 426-437. DOI: 10.1038/s41379-020-00653-1.
[5]	BHUSHAN B, APTE U. Liver Regeneration after acetaminophen hepatotoxicity: Mechanisms and therapeutic opportunities[J]. Am J Pathol, 2019, 189(4): 719-729. DOI: 10.1016/j.ajpath.2018.12.006.
[6]	DAKHOUL L, GHABRIL M, CHALASANI N. Drug-induced chronic liver injury[J]. J Hepatol, 2018, 69(1): 248-250. DOI: 10.1016/j.jhep.2018.01.001.
[7]	BONKOVSKY HL, KLEINER DE, GU J, et al. Clinical presentations and outcomes of bile duct loss caused by drugs and herbal and dietary supplements[J]. Hepatology, 2017, 65(4): 1267-1277. DOI: 10.1002/hep.28967.
[8]	GOODMAN ZD. Phenotypes and pathology of drug-induced liver disease[J]. Clin Liver Dis, 2017, 21(1): 89-101. DOI: 10.1016/j.cld.2016.08.006.
[9]	LEE B, JUNG EA, YOO JJ, et al. Prevalence, incidence and risk factors of tamoxifen-related non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Liver Int, 2020, 40(6): 1344-1355. DOI: 10.1111/liv.14434.
[10]	CAYET S, PASCO J, DUJARDIN F, et al. Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: Radio-pathological correlation[J]. Eur J Radiol, 2017, 94: 180-190. DOI: 10.1016/j.ejrad.2017.06.025.
[11]	CZECZOK TW, van ARNAM JS, WOOD LD, et al. The almost-normal liver biopsy: Presentation, clinical associations, and outcome[J]. Am J Surg Pathol, 2017, 41(9): 1247-1253. DOI: 10.1097/PAS.0000000000000881.
[12]	YANG YF. Road map of diagnosis in patients with unknown causes[J]. J Pract Hepatol, 2018, 21(1): 1-3. DOI: 10.3969/j.issn.1672-5069.2018.01.001. 杨永峰. 不明原因肝病诊断思路[J]. 实用肝脏病杂志, 2018, 21(1): 1-3. DOI: 10.3969/j.issn.1672-5069.2018.01.001.
[13]	KLEINER DE. The histopathological evaluation of drug-induced liver injury[J]. Histopathology, 2017, 70(1): 81-93. DOI: 10.1111/his.13082.
[14]	YU HY, GUO YY, YANG YF. Amoxicillin induced bile duct deletion drug-induced liver injury: A case report[J]. Chin Hepatol, 2018, 23(12): 1155-1156. DOI: 10.14000/j.cnki.issn.1008-1704. 2018.12.039. 俞海英, 郭银燕, 杨永峰. 阿莫西林导致胆管缺失型药物性肝损伤1例[J]. 肝脏, 2018, 23(12): 1155-1156. DOI: 10.14000/j.cnki.issn.1008-1704.2018.12.039.
[15]	LIU HL, YANG YF, XIONG QF, et al. Etiological analysis of hepatopathy of unknown etiology in 470 cases undergoing routine liver biopsy examination[J]. Chin J Hepatol, 2019, 27(11): 885-889. DOI: 10.3760/cma.j.issn.1007-3418.2019.11.012. 刘红丽, 杨永峰, 熊清芳, 等. 470例行肝穿刺活组织检查的不明原因肝病的病因分析[J]. 中华肝脏病杂志, 2019, 27(11): 885-889. DOI: 10.3760/cma.j.issn.1007-3418.2019.11.012.
[16]	KLEINER DE, CHALASANI NP, LEE WM, et al. Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations[J]. Hepatology, 2014, 59(2): 661-670. DOI: 10.1002/hep.26709.
[17]	COLLOREDO G, GUIDO M, SONZOGNI A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease[J]. J Hepatol, 2003, 39(2): 239-244. DOI: 10.1016/s0168-8278(03)00191-0.
[18]	NEUBERGER J, PATEL J, CALDWELL H, et al. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology[J]. Gut, 2020, 69(8): 1382-1403. DOI: 10.1136/gutjnl-2020-321299.
[19]	VIBHAKORN S, CHOLONGITAS E, KALAMBOKIS G, et al. A comparison of four- versus three-pass transjugular biopsy using a 19-G Tru-Cut needle and a randomized study using a cassette to prevent biopsy fragmentation[J]. Cardiovasc Intervent Radiol, 2009, 32(3): 508-513. DOI: 10.1007/s00270-008-9412-7.
[20]	KLEINER DE. Drug-induced liver injury: The hepatic pathologist's approach[J]. Gastroenterol Clin North Am, 2017, 46(2): 273-296. DOI: 10.1016/j.gtc.2017.01.004.
[21]	YANG YF. Improve the knowledge of liver pathology and related skills among clinicians engaged in hepatology[J]. 2018, 34(11): 2267-2270. DOI: 10.3969/j.issn.1001-5256.2018.11.001. 杨永峰. 提高肝病学科临床医师的病理修养[J]. 临床肝胆病杂志, 2018, 34(11): 2267-2270. DOI: 10.3969/j.issn.1001-5256.2018.11.001.